138614-30-9
中文名稱
艾替班特乙酸鹽
英文名稱
HOE-140
CAS
138614-30-9
分子式
C59H89N19O13S.C2H4O2
分子量
1364.59
MOL 文件
138614-30-9.mol
更新日期
2024/12/23 10:30:21
138614-30-9 結(jié)構(gòu)式
基本信息
中文別名
艾替班特乙酸鹽艾替班特 ACETATE
醋酸艾替班特(艾替班特乙酸鹽,HOE 140)
D-精氨酸基-L-精氨酸基-L-脯氨?；?(4R)-4-羥基-L-脯氨?；腔?3-(2-噻吩基)-L-丙氨?；?L-絲氨酰-(3R)-1,2,3,4-四氫-3-異喹啉羰基-(2S,3aS,7aS)-八氫-1H-吲哚-2-羰基-L-精氨酸 乙酸鹽
英文別名
FirazyrCS-1399
HOE 140 Acetate
lcatibant Acetate
HOE-140 (Icatibant)
HOE140
ICATIBANT
HOE 140
HOE 140 SYNTHETIC >99% SELECTIVE B2 BRAD YKIN
d-arg-l-arg-l-pro-l-hyp-gly-l-(2-thienyl)ala-l-ser-d-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-l-(2α,3β,7aβ)-octahydro-1h-indole-2-carbonyl-l-arg
Icatibant acetate, D-Arg-L-Arg-L-Pro-L-Hyp-Gly-L-(2-thienyl)Ala-L-Ser-D-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-L-(2α,3β,7aβ)-octahydro-1H-indole-2-carbonyl-L-Arg
(2S)-2-[[(3aS,7aS)-1-[2-[(2S)-2-[[(2S)-2-[[2-[[(4R)-1-[1-[2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxy-pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-yl-propanoyl]amino]-3-hydroxy-propanoyl]3,4-dihydro-1H-isoquinoline-3-carbonyl]2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid
所屬類別
生物化工：激動劑抑制劑物理化學性質(zhì)
儲存條件-20°C
溶解度DMSO:65.0(Max Conc. mg/mL);47.63(Max Conc. mM)
Ethanol:0.25(Max Conc. mg/mL);0.18(Max Conc. mM)
PBS (pH 7.2):10.0(Max Conc. mg/mL);7.33(Max Conc. mM)
Ethanol:0.25(Max Conc. mg/mL);0.18(Max Conc. mM)
PBS (pH 7.2):10.0(Max Conc. mg/mL);7.33(Max Conc. mM)
形態(tài)A crystalline solid
顏色White to off-white
艾替班特乙酸鹽價格(試劑級)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2024/11/08 | S5695 | 艾替班特乙酸鹽 Icatibant Acetate | 138614-30-9 | 2mg | 1204.11元 |
| 2024/11/08 | S5695 | 艾替班特乙酸鹽 Icatibant Acetate | 138614-30-9 | 5mg | 2212.24元 |
| 2024/11/08 | S5695 | Icatibant Acetate | 138614-30-9 | 25mg | 7126.16元 |
常見問題列表
生物活性
Icatibant Acetate是bradykinin B2受體的拮抗劑，可用于治療遺傳性血管性水腫。靶點
| Target | Value |
|
bradykinin B2 receptor
() |
體外研究
Icatibant (10-30 μM) potentiates angiotensin III, but not angiotensin II (contraction mediated by angiotensin AT1 receptors), and Lys-des-Arg9-bradykinin, but not des-Arg9-bradykinin (effects mediated by the bradykinin B1 receptors).
體內(nèi)研究
Icatibant (10-30 μM) potentiates angiotensin III, but not angiotensin II (contraction mediated by angiotensin AT1 receptors), and Lys-des-Arg9-bradykinin, but not des-Arg9-bradykinin (effects mediated by the bradykinin B1 receptors).
| Animal Model: | Female mice of the CBA/J (H-2 k ) strain. |
| Dosage: | 0.06, 0.3, or 1.5 mg/kg. |
| Administration: | Subcutaneous administration twice daily. |
| Result: | The length of the large intestine was 93.6±6.8 mm with the 1.5 mg/kg dosage and 94.0±4.1 mm with the 0.3 mg/kg dosage , showing a significant preventive effect on shortening. |